Perceptions, Expectations, Preferences, and Attitudes Toward Premature Ejaculation, Its Diagnosis and Topical Treatment with Fortacin™ Spray: Results from an Expert Panel Discussion

Figures & data

Table 1 Results from the Structured Questionnaire

Question		Answer	N (%)
1	How PE is perceived by the majority of your patients?	As a disease	5 (16.6)
		As a bother	25 (83.3)
2	How frequently do you perform an extensive diagnostic work-up including PROs-based questionnaires, stopwatch-measured IELT, laboratory and neuro-physiological tests in addition to history and physical examination in your patients with PE?	Always	3 (10.0)
		Sometimes	18 (60.0)
		Never	9 (30.0)
3	What is the main benefit expected by the majority of your patients from pharmacological therapy of PE?	Improved control over ejaculation	17 (56.5)
		Improved IELT	3 (10.0)
		Both	10 (33.3)
4	What dosage regimen is preferred by the majority of your patients with PE?	Daily	4 (13.3)
		On-demand	24 (80.0)
		Both	2 (6.6)
5	What route of administration is preferred by the majority of your patients with PE undergoing medical therapy?	Oral	12 (40.0)
		Topical	15 (50.0)
		Both	3 (10.0)
6	Is Fortacin™ efficacious in patients with acquired PE?	Yes	24 (80.0)
		No	6 (20.0)
7	Is the efficacy of Fortacin influenced by IELT?	Yes, it is higher in patients with IELT< 1min	4 (13.3)
		Yes, it is higher in patients with IELT>1min	5 (16.6)
		No, it is independent from IELT	21 (70.0)
8	The adherence to medical therapy, in the majority of your patients with PE is higher for:	Oral therapy	4 (13.3)
		Topical therapy	22 (73.3)
		Is not influenced by the route of administration	4 (13.3)

Abbreviations: IELT, intravaginal ejaculatory latency times; PE, premature ejaculation; PROs, patient reported outcomes.